{"id":"NCT00102518","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","briefTitle":"Aripiprazole Open-Label, Safety and Tolerability Study","officialTitle":"A Multi-Center, Open-Label, Safety and Tolerability Study of Flexible-Dose Oral Aripiprazole (2 Mg-30 mg) in the Treatment of Adolescent Patients With Schizophrenia and Child and Adolescent Patients With Bipolar I Disorder, Manic or Mixed Episode With or Without Psychotic Features","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-09","primaryCompletion":"2007-02","completion":"2007-02","firstPosted":"2005-01-31","resultsPosted":"2012-08-31","lastUpdate":"2012-08-31"},"enrollment":325,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Schizophrenia","Bipolar Disorder"],"interventions":[{"type":"DRUG","name":"Aripiprazole","otherNames":["OPC-14597"]}],"arms":[{"label":"NCT00102063 and NCT00110461 Subjects","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia, and child and adolescent patients with bipolar I disorder, manic or mixed episode.","primaryOutcome":{"measure":"Percentage of Subjects Experiencing SAEs","timeFrame":"Baseline and Week 23","effectByArm":[{"arm":"NCT00102063 and NCT00110461 Subjects","deltaMin":6.2,"sd":null}],"pValues":[]},"eligibility":{"minAge":"10 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":2},"locations":{"siteCount":50,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":325},"commonTop":["Extrapyramidal disorder","Somnolence","Headache","Akathisia","Insomnia"]}}